The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.
Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.
A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.
Publications found:
9,295
Sort by:
Lipopolysaccharide (Endotoxin) - Drugs in Development, 2021
US$ 3,000.00
Lipopolysaccharide (Endotoxin) - Drugs in Development, 2021 SUMMARY Lipopolysaccharide (Endotoxin) - Drugs in Development, 2021 provides in depth analysis on Lipopolysaccharide (Endotoxin) targeted pi...
April 2021
45 pages
Liposarcoma (Oncology) - Drugs in Development, 2021
US$ 2,000.00
Liposarcoma (Oncology) - Drugs in Development, 2021 SUMMARY Liposarcoma (Oncology) - Drugs in Development, 2021 provides an overview of the Liposarcoma pipeline landscape. The report provides comprehe...
April 2021
80 pages
Liver Cancer (Oncology) - Drugs in Development, 2021
US$ 2,500.00
Liver Cancer (Oncology) - Drugs in Development, 2021 SUMMARY Liver Cancer (Oncology) - Drugs in Development, 2021 provides an overview of the Liver Cancer pipeline landscape. The report provides compr...
April 2021
325 pages
Liver X Receptor (LXR) - Drugs in Development, 2021
US$ 3,000.00
Liver X Receptor (LXR) - Drugs in Development, 2021 SUMMARY Liver X Receptor (LXR) - Drugs in Development, 2021 provides in depth analysis on Liver X Receptor (LXR) targeted pipeline therapeutics. The...
April 2021
30 pages
Low-Grade Glioma (Oncology) - Drugs in Development, 2021
US$ 2,000.00
Low-Grade Glioma (Oncology) - Drugs in Development, 2021 SUMMARY Low-Grade Glioma (Oncology) - Drugs in Development, 2021 provides an overview of the Low-Grade Glioma pipeline landscape. The report pr...
April 2021
50 pages
Lung Adenocarcinoma (Oncology) - Drugs in Development, 2021
US$ 2,000.00
Lung Adenocarcinoma (Oncology) - Drugs in Development, 2021 SUMMARY Lung Adenocarcinoma (Oncology) - Drugs in Development, 2021 provides an overview of the Lung Adenocarcinoma pipeline landscape. The...
April 2021
100 pages
Lung Disease (Respiratory) - Drugs in Development, 2021
US$ 2,000.00
Lung Disease (Respiratory) - Drugs in Development, 2021 SUMMARY Lung Disease (Respiratory) - Drugs in Development, 2021 provides an overview of the Lung Disease pipeline landscape. The report provides...
April 2021
85 pages
Lung Infections (Respiratory) - Drugs in Development, 2021
US$ 2,000.00
Lung Infections (Respiratory) - Drugs in Development, 2021 SUMMARY Lung Infections (Respiratory) - Drugs in Development, 2021 provides an overview of the Lung Infections pipeline landscape. The report...
April 2021
45 pages
Lung Injury (Respiratory) - Drugs in Development, 2021
US$ 2,000.00
Lung Injury (Respiratory) - Drugs in Development, 2021 SUMMARY Lung Injury (Respiratory) - Drugs in Development, 2021 provides an overview of the Lung Injury pipeline landscape. The report provides co...
April 2021
50 pages
Lupus Nephritis (Immunology) - Drugs in Development, 2021
US$ 2,000.00
Lupus Nephritis (Immunology) - Drugs in Development, 2021 SUMMARY Lupus Nephritis (Immunology) - Drugs in Development, 2021 provides an overview of the Lupus Nephritis pipeline landscape. The report p...
April 2021
90 pages
Malignant Ascites (Oncology) - Drugs in Development, 2021
US$ 2,000.00
Malignant Ascites (Oncology) - Drugs in Development, 2021 SUMMARY Malignant Ascites (Oncology) - Drugs in Development, 2021 provides an overview of the Malignant Ascites pipeline landscape. The report...
April 2021
30 pages
Malignant Glioma (Oncology) - Drugs in Development, 2021
US$ 2,000.00
Malignant Glioma (Oncology) - Drugs in Development, 2021 SUMMARY Malignant Glioma (Oncology) - Drugs in Development, 2021 provides an overview of the Malignant Glioma pipeline landscape. The report pr...
April 2021
90 pages
Malignant Neoplasms (Oncology) - Drugs in Development, 2021
US$ 2,000.00
Malignant Neoplasms (Oncology) - Drugs in Development, 2021 SUMMARY Malignant Neoplasms (Oncology) - Drugs in Development, 2021 provides an overview of the Malignant Neoplasms pipeline landscape. The...
April 2021
45 pages
Mast Cell Leukemia (Oncology) - Drugs in Development, 2021
US$ 2,000.00
Mast Cell Leukemia (Oncology) - Drugs in Development, 2021 SUMMARY Mast Cell Leukemia (Oncology) - Drugs in Development, 2021 provides an overview of the Mast Cell Leukemia pipeline landscape. The rep...
April 2021
30 pages
Meningioma (Oncology) - Drugs in Development, 2021
US$ 2,000.00
Meningioma (Oncology) - Drugs in Development, 2021 SUMMARY Meningioma (Oncology) - Drugs in Development, 2021 provides an overview of the Meningioma pipeline landscape. The report provides comprehensi...
April 2021
55 pages
